BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 32413024)

  • 1. Estrogen receptor β exerts tumor suppressive effects in prostate cancer through repression of androgen receptor activity.
    Chaurasiya S; Widmann S; Botero C; Lin CY; Gustafsson JÅ; Strom AM
    PLoS One; 2020; 15(5):e0226057. PubMed ID: 32413024
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Estrogen induces androgen-repressed SOX4 expression to promote progression of prostate cancer cells.
    Yang M; Wang J; Wang L; Shen C; Su B; Qi M; Hu J; Gao W; Tan W; Han B
    Prostate; 2015 Sep; 75(13):1363-75. PubMed ID: 26015225
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oestrogen receptor beta is required for androgen-stimulated proliferation of LNCaP prostate cancer cells.
    Maggiolini M; Recchia AG; Carpino A; Vivacqua A; Fasanella G; Rago V; Pezzi V; Briand PA; Picard D; Andò S
    J Mol Endocrinol; 2004 Jun; 32(3):777-91. PubMed ID: 15171712
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A regulatory feedback loop between Ca2+/calmodulin-dependent protein kinase kinase 2 (CaMKK2) and the androgen receptor in prostate cancer progression.
    Karacosta LG; Foster BA; Azabdaftari G; Feliciano DM; Edelman AM
    J Biol Chem; 2012 Jul; 287(29):24832-43. PubMed ID: 22654108
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GLUT12 promotes prostate cancer cell growth and is regulated by androgens and CaMKK2 signaling.
    White MA; Tsouko E; Lin C; Rajapakshe K; Spencer JM; Wilkenfeld SR; Vakili SS; Pulliam TL; Awad D; Nikolos F; Katreddy RR; Kaipparettu BA; Sreekumar A; Zhang X; Cheung E; Coarfa C; Frigo DE
    Endocr Relat Cancer; 2018 Apr; 25(4):453-469. PubMed ID: 29431615
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Down-regulation of calcium/calmodulin-dependent protein kinase kinase 2 by androgen deprivation induces castration-resistant prostate cancer.
    Shima T; Mizokami A; Miyagi T; Kawai K; Izumi K; Kumaki M; Ofude M; Zhang J; Keller ET; Namiki M
    Prostate; 2012 Dec; 72(16):1789-801. PubMed ID: 22549914
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Unique bisphenol A transcriptome in prostate cancer: novel effects on ERbeta expression that correspond to androgen receptor mutation status.
    Hess-Wilson JK; Webb SL; Daly HK; Leung YK; Boldison J; Comstock CE; Sartor MA; Ho SM; Knudsen KE
    Environ Health Perspect; 2007 Nov; 115(11):1646-53. PubMed ID: 18007998
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Central role for PELP1 in nonandrogenic activation of the androgen receptor in prostate cancer.
    Yang L; Ravindranathan P; Ramanan M; Kapur P; Hammes SR; Hsieh JT; Raj GV
    Mol Endocrinol; 2012 Apr; 26(4):550-61. PubMed ID: 22403175
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nucleoporin 62 and Ca(2+)/calmodulin dependent kinase kinase 2 regulate androgen receptor activity in castrate resistant prostate cancer cells.
    Karacosta LG; Kuroski LA; Hofmann WA; Azabdaftari G; Mastri M; Gocher AM; Dai S; Hoste AJ; Edelman AM
    Prostate; 2016 Feb; 76(3):294-306. PubMed ID: 26552607
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dehydroepiandrosterone administration or G{alpha}q overexpression induces {beta}-catenin/T-Cell factor signaling and growth via increasing association of estrogen receptor-{beta}/Dishevelled2 in androgen-independent prostate cancer cells.
    Liu X; Arnold JT; Blackman MR
    Endocrinology; 2010 Apr; 151(4):1428-40. PubMed ID: 20176724
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Estrogen receptor β, a regulator of androgen receptor signaling in the mouse ventral prostate.
    Wu WF; Maneix L; Insunza J; Nalvarte I; Antonson P; Kere J; Yu NY; Tohonen V; Katayama S; Einarsdottir E; Krjutskov K; Dai YB; Huang B; Su W; Warner M; Gustafsson JÅ
    Proc Natl Acad Sci U S A; 2017 May; 114(19):E3816-E3822. PubMed ID: 28439009
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estrogen receptor-beta activated apoptosis in benign hyperplasia and cancer of the prostate is androgen independent and TNFalpha mediated.
    McPherson SJ; Hussain S; Balanathan P; Hedwards SL; Niranjan B; Grant M; Chandrasiri UP; Toivanen R; Wang Y; Taylor RA; Risbridger GP
    Proc Natl Acad Sci U S A; 2010 Feb; 107(7):3123-8. PubMed ID: 20133657
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DNA demethylation and histone deacetylation inhibition co-operate to re-express estrogen receptor beta and induce apoptosis in prostate cancer cell-lines.
    Walton TJ; Li G; Seth R; McArdle SE; Bishop MC; Rees RC
    Prostate; 2008 Feb; 68(2):210-22. PubMed ID: 18092350
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bakuchiol exhibits anti-metastasis activity through NF-κB cross-talk signaling with AR and ERβ in androgen-independent prostate cancer cells PC-3.
    Miao L; Yun X; Tao R; Wang Y; Fan G; Zhu Y; Cai T; Zhu Z; Yan C; Gao X
    J Pharmacol Sci; 2018 Sep; 138(1):1-8. PubMed ID: 30236540
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro chronic administration of ERbeta selective ligands and prostate cancer cell growth: hypotheses on the selective role of 3beta-adiol in AR-positive RV1 cells.
    Colciago A; Ruscica M; Mornati O; Piccolella M; Montagnani-Marelli M; Eberini I; Festuccia C; Magni P; Motta M; Negri-Cesi P
    Biomed Res Int; 2014; 2014():801473. PubMed ID: 24877132
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative effects of DHEA vs. testosterone, dihydrotestosterone, and estradiol on proliferation and gene expression in human LNCaP prostate cancer cells.
    Arnold JT; Le H; McFann KK; Blackman MR
    Am J Physiol Endocrinol Metab; 2005 Mar; 288(3):E573-84. PubMed ID: 15536203
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Estrogen receptor beta (ERβ) mediates expression of β-catenin and proliferation in prostate cancer cell line PC-3.
    Lombardi AP; Pisolato R; Vicente CM; Lazari MF; Lucas TF; Porto CS
    Mol Cell Endocrinol; 2016 Jul; 430():12-24. PubMed ID: 27107935
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interleukin-6 regulates androgen receptor activity and prostate cancer cell growth.
    Culig Z; Bartsch G; Hobisch A
    Mol Cell Endocrinol; 2002 Nov; 197(1-2):231-8. PubMed ID: 12431817
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Raloxifene induces cell death and inhibits proliferation through multiple signaling pathways in prostate cancer cells expressing different levels of estrogen receptor α and β.
    Rossi V; Bellastella G; De Rosa C; Abbondanza C; Visconti D; Maione L; Chieffi P; Della Ragione F; Prezioso D; De Bellis A; Bellastella A; Sinisi AA
    J Cell Physiol; 2011 May; 226(5):1334-9. PubMed ID: 20945400
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The immunophilin ligands cyclosporin A and FK506 suppress prostate cancer cell growth by androgen receptor-dependent and -independent mechanisms.
    Periyasamy S; Warrier M; Tillekeratne MP; Shou W; Sanchez ER
    Endocrinology; 2007 Oct; 148(10):4716-26. PubMed ID: 17615153
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.